Asociacion Instituto De Investigacion Sanitaria Biobizkaia
- Address
- lock Available on a paid plan
Neurology Research
At Asociacion Instituto De Investigacion Sanitaria Biobizkaia, the Neurology portfolio includes clinical research focused on Parkinson's Disease and the broader field of nervous system diseases. These studies are designed to assess new approaches that may help improve tremor control, daily function, and overall symptom management for people living with movement disorders.
- Evaluation of a new therapy aimed at reducing residual tremor and improving functional performance in Parkinson's Disease
- Research centered on nervous system diseases with a focus on symptom relief and quality-of-life outcomes
This work reflects a practical effort to advance treatment options in a common neurological condition, with attention to both symptom improvement and everyday patient impact.
Oncology Research
The site also supports oncology studies across neoplasms, including research in metastatic non-small cell lung cancer. These trials are exploring whether newer cancer treatments can perform better than established options, especially for patients whose disease has progressed after earlier immunotherapy.
- Testing a therapeutic cancer vaccine approach for metastatic non-small cell lung cancer
- Comparing a new treatment strategy with standard chemotherapy to assess survival benefit in advanced cancer
The focus is on improving treatment effectiveness and extending survival in difficult-to-treat cancer settings.
Dermatology and Skin Cancer Research
Clinical research in skin and connective tissue diseases at this research site includes studies in basal cell carcinoma. The trials are examining whether locally delivered investigational therapy can be safe, well tolerated, and potentially effective for patients with resectable disease.
- Assessing a novel treatment for basal cell carcinoma in patients with surgically treatable tumors
- Studying whether local therapy can support better disease control while preserving treatment tolerability
This line of research aims to improve options for common skin cancer care, with a strong interest in both safety and early signs of benefit.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Xenon Pharmaceuticals Inc.2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Xenon Pharmaceuticals Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Asociacion Instituto De Investigacion Sanitaria Biobizkaia
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy (X-TOLE4) | Xenon Pharmaceuticals Inc. | Phase III | Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Azetukalner | 2 | Unknown | 2023-09-27 | 2024-02-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.